{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:44:58Z","timestamp":1790675098220,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,3,30]],"date-time":"2020-03-30T00:00:00Z","timestamp":1585526400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,3,30]],"date-time":"2020-03-30T00:00:00Z","timestamp":1585526400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["70112548"],"award-info":[{"award-number":["70112548"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Clinician Scientist Program of the Faculty of Medicine Tuebingen","award":["364-0-0"],"award-info":[{"award-number":["364-0-0"]}]},{"name":"Clinician Scientist Program of the Faculty of Medicine Tuebingen","award":["390-0-0"],"award-info":[{"award-number":["390-0-0"]}]},{"name":"Junior Research Group Grant of the Interdisciplinary Centre for Clinical Research","award":["2383-0-0"],"award-info":[{"award-number":["2383-0-0"]}]},{"name":"Cancer Award of Wuerttemberg"},{"name":"IZKF Postgraduate Program of the Faculty of Medicine Tuebingen","award":["2019-1-18"],"award-info":[{"award-number":["2019-1-18"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>Systemic sclerosis (SSc) is a connective tissue disease with a significant morbidity and reduced survival of patients. Effective treatment and clinical control of the disease remain challenging. In particular, the development of pulmonary and cardiac fibrosis and pulmonary hypertension are severe complications responsible for excessive mortality. Currently available treatment strategies only alleviate symptoms and slow disease progression. Here, we investigated the therapeutic potential of ibrutinib, a Bruton\u2019s tyrosine kinase (BTK) inhibitor used in B cell malignancies, to alter B cell pathology in SSc in an in vitro model of autoimmunity.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>PBMCs and sorted B cells of 24 patients with SSc were used for functional testing after stimulation with hypomethylated DNA fragments (CpG) to induce an innate immune response. The effects of ibrutinib on cytokine production, autoantibody release, and activation of the transcription factor NF\u03baB were evaluated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Ibrutinib was able to reduce the production of the profibrotic hallmark cytokines IL-6 and TNF-\u03b1 mainly from the effector B cell population in patients with SSc. Importantly, small doses of ibrutinib (0.1\u2009\u03bcM) preserved the production of immunoregulatory IL-10 while effectively inhibiting hyperactivated, profibrotic effector B cells. In a flow cytometry analysis of phosphorylated NF\u03baB, an important transcription factor in the induction of innate immune responses in B cells, significantly less activation was observed with ibrutinib treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our data could pave the avenue for a clinical application of ibrutinib for patients with SSc as a novel treatment option for the underlying pathogenetic immune imbalance contributing to disease onset and progression.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13075-020-02153-8","type":"journal-article","created":{"date-parts":[[2020,3,30]],"date-time":"2020-03-30T17:02:42Z","timestamp":1585587762000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Inhibition of effector B cells by ibrutinib in systemic sclerosis"],"prefix":"10.1186","volume":"22","author":[{"given":"Jakob","family":"Einhaus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Christin","family":"Pecher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Asteriti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannes","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy-Ann","family":"Secker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Duerr-Stoerzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hildegard","family":"Keppeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhild","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corina","family":"Schneidawind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg","family":"Henes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Schneidawind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,30]]},"reference":[{"key":"2153_CR1","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.semarthrit.2014.05.010","volume":"44","author":"M Rubio-Rivas","year":"2014","unstructured":"Rubio-Rivas M, Royo C, Sime\u00f3n CP, Corbella X, Fonollosa V. Mortality and survival in systemic sclerosis: systematic review and meta-analysis. Semin Arthritis Rheum. 2014;44:208\u201319.","journal-title":"Semin Arthritis Rheum"},{"key":"2153_CR2","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1136\/annrheumdis-2017-211448","volume":"76","author":"M Elhai","year":"2017","unstructured":"Elhai M, et al. Mapping and predicting mortality from systemic sclerosis. Ann Rheum Dis. 2017;76:1897\u2013905.","journal-title":"Ann Rheum Dis"},{"key":"2153_CR3","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1136\/ard.2009.114264","volume":"69","author":"AJ Tyndall","year":"2010","unstructured":"Tyndall AJ, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis. 2010;69:1809\u201315.","journal-title":"Ann Rheum Dis"},{"key":"2153_CR4","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","volume":"76","author":"O Kowal-Bielecka","year":"2017","unstructured":"Kowal-Bielecka O, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76:1327\u201339.","journal-title":"Ann Rheum Dis"},{"key":"2153_CR5","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1093\/rheumatology\/kev331","volume":"55","author":"T Matsushita","year":"2016","unstructured":"Matsushita T, Hamaguchi Y, Hasegawa M, Takehara K, Fujimoto M. Decreased levels of regulatory B cells in patients with systemic sclerosis: association with autoantibody production and disease activity. Rheumatology. 2016;55:263\u20137.","journal-title":"Rheumatology"},{"key":"2153_CR6","doi-asserted-by":"publisher","first-page":"eaas9944","DOI":"10.1126\/sciadv.aas9944","volume":"4","author":"T Matsushita","year":"2018","unstructured":"Matsushita T, et al. BAFF inhibition attenuates fibrosis in scleroderma by modulating the regulatory and effector B cell balance. Sci Adv. 2018;4:eaas9944.","journal-title":"Sci Adv"},{"key":"2153_CR7","unstructured":"Khanna D, et al. Efficacy and Safety of Tocilizumab for the Treatment of Systemic Sclerosis: results from a Phase 3 Randomized Controlled Trial [abstract]. Arthritis Rheumatol. 2018;70(suppl 10) https:\/\/acrabstracts.org\/abstract\/efficacy-and-safety-of-tocilizumab-for-the-treatment-of-systemic-sclerosis-results-from-a-phase-3-randomized-controlled-trial\/. Accessed 14 Dec 2019."},{"key":"2153_CR8","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1136\/annrheumdis-2013-204522","volume":"74","author":"S Jordan","year":"2015","unstructured":"Jordan S, et al. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis. 2015;74:1188\u201394.","journal-title":"Ann Rheum Dis"},{"key":"2153_CR9","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa1215637","volume":"369","author":"JC Byrd","year":"2013","unstructured":"Byrd JC, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369:32\u201342.","journal-title":"N Engl J Med"},{"key":"2153_CR10","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1056\/NEJMoa1306220","volume":"369","author":"ML Wang","year":"2013","unstructured":"Wang ML, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369:507\u201316.","journal-title":"N Engl J Med"},{"key":"2153_CR11","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1002\/art.39655","volume":"68","author":"F Fang","year":"2016","unstructured":"Fang F, et al. Toll-like receptor 9 signaling is augmented in systemic sclerosis and elicits transforming growth factor \u03b2-dependent fibroblast activation: TLR9 signaling promotes fibrotic responses. Arthritis Rheumatol. 2016;68:1989\u20132002.","journal-title":"Arthritis Rheumatol"},{"key":"2153_CR12","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.molmed.2007.09.002","volume":"13","author":"T Kawai","year":"2007","unstructured":"Kawai T, Akira S. Signaling to NF-\u03baB by Toll-like receptors. Trends Mol Med. 2007;13:460\u20139.","journal-title":"Trends Mol Med"},{"key":"2153_CR13","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/ni823","volume":"3","author":"TT Su","year":"2002","unstructured":"Su TT, et al. PKC-\u03b2 controls I\u03baB kinase lipid raft recruitment and activation in response to BCR signaling. Nat Immunol. 2002;3:780\u20136.","journal-title":"Nat Immunol"},{"key":"2153_CR14","doi-asserted-by":"publisher","first-page":"13075","DOI":"10.1073\/pnas.1004594107","volume":"107","author":"LA Honigberg","year":"2010","unstructured":"Honigberg LA, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci. 2010;107:13075\u201380.","journal-title":"Proc Natl Acad Sci"},{"key":"2153_CR15","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1038\/nri955","volume":"2","author":"H Niiro","year":"2002","unstructured":"Niiro H, Clark EA. Regulation of B-cell fate by antigen-receptor signals. Nat Rev Immunol. 2002;2:945\u201356.","journal-title":"Nat Rev Immunol"},{"key":"2153_CR16","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","volume":"31","author":"RH Advani","year":"2013","unstructured":"Advani RH, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies. J Clin Oncol. 2013;31:88\u201394.","journal-title":"J Clin Oncol"},{"key":"2153_CR17","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1182\/bloodadvances.2018028761","volume":"3","author":"SE Coutre","year":"2019","unstructured":"Coutre SE, et al. Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. Blood Adv. 2019;3:1799\u2013807.","journal-title":"Blood Adv"},{"key":"2153_CR18","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/cmdc.200600221","volume":"2","author":"Z Pan","year":"2007","unstructured":"Pan Z, et al. Discovery of selective irreversible inhibitors for Bruton\u2019s tyrosine kinase. ChemMedChem. 2007;2:58\u201361.","journal-title":"ChemMedChem"},{"key":"2153_CR19","doi-asserted-by":"publisher","unstructured":"Brown M, O\u2019Reilly S. The immunopathogenesis of fibrosis in systemic sclerosis. Clin Exp Immunol. 2018. https:\/\/doi.org\/10.1111\/cei.13238.","DOI":"10.1111\/cei.13238"},{"key":"2153_CR20","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.revmed.2016.02.016","volume":"38","author":"S Sanges","year":"2017","unstructured":"Sanges S, et al. Role of B cells in the pathogenesis of systemic sclerosis. Rev M\u00e9d Interne. 2017;38:113\u201324.","journal-title":"Rev M\u00e9d Interne"},{"key":"2153_CR21","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1084\/jem.186.11.1923","volume":"186","author":"M Inaoki","year":"1997","unstructured":"Inaoki M, Sato S, Weintraub BC, Goodnow CC, Tedder TF. CD19-regulated signaling thresholds control peripheral tolerance and autoantibody production in B lymphocytes. J Exp Med. 1997;186:1923\u201331.","journal-title":"J Exp Med"},{"key":"2153_CR22","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/S0002-9440(10)63328-7","volume":"165","author":"N Asano","year":"2004","unstructured":"Asano N, et al. B lymphocyte signaling established by the CD19\/CD22 loop regulates autoimmunity in the tight-skin mouse. Am J Pathol. 2004;165:641\u201350.","journal-title":"Am J Pathol"},{"key":"2153_CR23","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1172\/JCI0215078","volume":"109","author":"E Saito","year":"2002","unstructured":"Saito E, et al. CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse. J Clin Invest. 2002;109:1453\u201362.","journal-title":"J Clin Invest"},{"key":"2153_CR24","doi-asserted-by":"crossref","unstructured":"Pone EJ, et al. BCR-signalling synergizes with TLR-signalling for induction of AID and immunoglobulin class-switching through the non-canonical NF-\u03baB pathway. Nat Commun. 2012;3:767.","DOI":"10.1038\/ncomms1769"},{"key":"2153_CR25","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1080\/03009740902758875","volume":"38","author":"W Lei","year":"2009","unstructured":"Lei W, et al. Abnormal DNA methylation in CD4+ T cells from patients with systemic lupus erythematosus, systemic sclerosis, and dermatomyositis. Scand J Rheumatol. 2009;38:369\u201374.","journal-title":"Scand J Rheumatol"},{"key":"2153_CR26","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/nri1957","volume":"6","author":"A Marshak-Rothstein","year":"2006","unstructured":"Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol. 2006;6:823\u201335.","journal-title":"Nat Rev Immunol"},{"key":"2153_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/cti.2013.2","volume":"2","author":"S O\u2019Reilly","year":"2013","unstructured":"O\u2019Reilly S, Cant R, Ciechomska M, van Laar JM. Interleukin-6: a new therapeutic target in systemic sclerosis? Clin Transl Immunol. 2013;2:e4.","journal-title":"Clin Transl Immunol"},{"key":"2153_CR28","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1038\/nm.2807","volume":"18","author":"TA Wynn","year":"2012","unstructured":"Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med. 2012;18:1028\u201340.","journal-title":"Nat Med"},{"key":"2153_CR29","doi-asserted-by":"crossref","unstructured":"Rip J, et al. Toll-like receptor signaling drives Btk-mediated autoimmune disease. Front Immunol. 2019;10:95.","DOI":"10.3389\/fimmu.2019.00095"},{"key":"2153_CR30","doi-asserted-by":"crossref","unstructured":"Kayser C, Fritzler MJ. Autoantibodies in systemic sclerosis: unanswered questions. Front Immunol. 2015;6:167.","DOI":"10.3389\/fimmu.2015.00167"},{"key":"2153_CR31","doi-asserted-by":"publisher","first-page":"3265","DOI":"10.1002\/art.20515","volume":"50","author":"J H\u00e9nault","year":"2004","unstructured":"H\u00e9nault J, Tremblay M, Cl\u00e9ment I, Raymond Y, Sen\u00e9cal J-L. Direct binding of anti-DNA topoisomerase I autoantibodies to the cell surface of fibroblasts in patients with systemic sclerosis: antifibroblast autoantibodies in SSc. Arthritis Rheum. 2004;50:3265\u201374.","journal-title":"Arthritis Rheum"},{"key":"2153_CR32","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1002\/art.39437","volume":"68","author":"A Mavropoulos","year":"2016","unstructured":"Mavropoulos A, et al. Breg cells are numerically decreased and functionally impaired in patients with systemic sclerosis: Breg cells in systemic sclerosis. Arthritis Rheumatol. 2016;68:494\u2013504.","journal-title":"Arthritis Rheumatol"},{"key":"2153_CR33","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/j.1365-2249.2004.02642.x","volume":"138","author":"E Scala","year":"2004","unstructured":"Scala E, et al. Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement. Clin Exp Immunol. 2004;138:540\u20136.","journal-title":"Clin Exp Immunol"},{"key":"2153_CR34","doi-asserted-by":"publisher","first-page":"R147","DOI":"10.1186\/ar2821","volume":"11","author":"P Gourh","year":"2009","unstructured":"Gourh P, et al. Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations. Arthritis Res Ther. 2009;11:R147.","journal-title":"Arthritis Res Ther"},{"key":"2153_CR35","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.autrev.2010.08.003","volume":"10","author":"J Baraut","year":"2010","unstructured":"Baraut J, Michel L, Verrecchia F, Farge D. Relationship between cytokine profiles and clinical outcomes in patients with systemic sclerosis. Autoimmun Rev. 2010;10:65\u201373.","journal-title":"Autoimmun Rev"},{"key":"2153_CR36","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/1346-8138.13184","volume":"43","author":"A Yoshizaki","year":"2016","unstructured":"Yoshizaki A. B lymphocytes in systemic sclerosis: abnormalities and therapeutic targets. J Dermatol. 2016;43:39\u201345.","journal-title":"J Dermatol"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-020-02153-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13075-020-02153-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-020-02153-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,29]],"date-time":"2021-03-29T23:07:08Z","timestamp":1617059228000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-020-02153-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,30]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2153"],"URL":"https:\/\/doi.org\/10.1186\/s13075-020-02153-8","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,30]]},"assertion":[{"value":"20 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the institutional review board of the Eberhard-Karls-University Tuebingen (IRB approval number 114\/2016BO) to be in accordance with the ethical standards and with the Helsinki Declaration of 1975, as revised in 2013.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"66"}}